NASDAQ:RAPT 20 January 2026 - 22 January 2026

GSK shares ticked up in early London trading Thursday as investors weighed the drugmaker’s push into a mid-stage food-allergy treatment alongside growing discussions over vaccine demand in the U.S.

RAPT Therapeutics shares jumped about 64% Tuesday, reaching $57.54 in early Nasdaq action. The uptick followed Britain’s GSK unveiling a cash acquisition offer of $58 per share for the U.S. biotech firm.